$IBIO If AEMD is running, we should not be far behind since we will be a supplier... NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the establishment of an agreement with Aethlon Medical, Inc. (Nasdaq:AEMD) to support potential large-scale production of the Aethlon Hemopurifier® blood purification device. Aethlon Medical is a therapeutic technology company focused on unmet needs in global health and biodefense.
@pitkineagle Never saw the end of contract notice? They told us when UTHR puller out, and that was why I bought back in 2019 for artificial lung creation using bio inks. I am sad about ibio, but not forgotten.